What is the recommended loading dose of phenytoin, including dosage, maximum total dose, infusion rate, and special considerations for patients with cardiac disease, hepatic impairment, or the elderly?

Phenytoin Loading Dose

For status epilepticus or acute seizure management, administer phenytoin 15-20 mg/kg IV at a maximum infusion rate of 50 mg/min in adults (or 1-3 mg/kg/min in children, whichever is slower), with continuous cardiac monitoring required throughout the infusion. 1

Standard Loading Dose

Adults:

• Loading dose: 15-20 mg/kg IV 1
• Maximum infusion rate: 50 mg/min 1
• Alternative dosing: 10-15 mg/kg for non-emergent loading 1

Pediatric patients:

• Neonates: 10 mg/kg IV 2
• Children: 15-20 mg/kg IV 2
• Maximum infusion rate: 1-3 mg/kg/min or 50 mg/min, whichever is slower 2, 1
• Infusion time: 10-20 minutes recommended 2

Maximum Total Dose

• Initial maximum: 1000 mg (1 gram) 2
• Repeat dosing: May repeat once after 15 minutes if seizures persist 2
• Maximum cumulative dose: 40 mg/kg total 2

Infusion Rate Specifications

The infusion rate is critical for preventing cardiovascular complications:

• Standard rate: 50 mg/min maximum in adults without cardiac disease 1, 3
• Slower rate required: 25 mg/min for patients >50 years or with atherosclerotic cardiovascular disease 3
• Pediatric rate: Not to exceed 1 mg/kg/min 2

Research demonstrates that the 50 mg/min rate is safe in younger patients without cardiovascular disease, but significantly more cardiovascular side effects (hypotension and bradycardia) occur in older patients or those with cardiac disease at this rate 3.

Special Population Considerations

Cardiac Disease

Reduce infusion rate to 25 mg/min or slower 3. Continuous ECG and blood pressure monitoring is mandatory 1. The drug may cause hypotension, bradyarrhythmias, and cardiac arrest, especially with rapid infusion 2, 1. Monitor heart rate and reduce infusion rate if heart rate decreases by 10 beats per minute 2.

Hepatic Impairment

• Monitor unbound (free) phenytoin concentrations rather than total levels 1
• The fraction of unbound phenytoin increases significantly in hepatic disease 1
• Consider dose reduction and slower infusion rates (25-50% reduction recommended) 4
• Phenytoin undergoes extensive hepatic metabolism and should be used cautiously 5

Elderly Patients

• Reduce infusion rate by 25-50% 4
• Use maximum 25 mg/min infusion rate 3
• Monitor unbound phenytoin levels if hypoalbuminemia present 1
• Elderly patients have decreased protein binding capacity, leading to higher free drug concentrations 4

Renal Impairment

• Monitor unbound phenytoin concentrations 1
• Protein binding is decreased, increasing free drug fraction 1
• No specific dose adjustment for loading, but monitor closely 1

Hypoalbuminemia

• Monitor unbound phenytoin levels (therapeutic range: 1-2 mcg/mL unbound) 1
• Total phenytoin levels may be misleadingly low despite adequate free drug concentrations 1

Administration Details

Preparation and Compatibility

• Dilute in normal saline only - incompatible with glucose-containing solutions 2
• Requires filter and infusion pump for IV administration 6
• Do not refrigerate or freeze; precipitation may occur but will redissolve at room temperature 1

Monitoring Requirements

• Continuous ECG monitoring throughout infusion 1
• Blood pressure monitoring - continuous arterial line preferred for high-risk patients 1
• Respiratory monitoring - prepare for respiratory support 2
• Heart rate monitoring - reduce rate if HR drops by 10 bpm 2

Timing of Serum Levels

• Peak levels: Obtained at expected peak concentration to assess toxicity threshold 1
• Trough levels: Obtained just before next scheduled dose for therapeutic monitoring 1
• Therapeutic range: 10-20 mcg/mL total (1-2 mcg/mL unbound) 1

Critical Safety Warnings

Cardiovascular Toxicity

The most serious risk is cardiovascular collapse with rapid infusion. Never exceed 50 mg/min in any patient 1. Case reports document deaths associated with infusion rates >50 mg/min 7. In contrast, clinical trials using recommended rates show no serious cardiovascular mortality 7.

Alternative: Fosphenytoin

Fosphenytoin is preferred when available due to lower cardiac toxicity risk 2. It can be administered at 150 PE/min (three times faster than phenytoin) with fewer cardiovascular effects 4. Dosing is 15-20 PE/kg IV at 1-3 PE/kg/min (maximum 150 PE/min) 2.

Purple Glove Syndrome

Risk of local tissue necrosis and purple glove syndrome with extravasation 1. Intramuscular administration should NOT be used for status epilepticus as peak levels may take up to 24 hours 1.

Drug Interactions

Phenytoin has extensive drug interactions due to hepatic enzyme induction. Monitor closely when used with other highly protein-bound drugs 4.

Practical Loading Algorithm

1. Assess patient risk factors: Age >50, cardiac disease, hepatic/renal impairment, hypoalbuminemia
2. Choose infusion rate:
   • Low risk: 50 mg/min
   • High risk: 25 mg/min or slower
3. Prepare: Dilute in normal saline, establish continuous monitoring
4. Administer: 15-20 mg/kg (maximum 1000 mg initial dose)
5. Monitor: ECG, BP, respiratory status throughout
6. Adjust: Slow or stop if HR drops >10 bpm, hypotension, or arrhythmia develops
7. Repeat if needed: After 15 minutes, may give second dose (maximum total 40 mg/kg)
8. Follow-up: Check phenytoin level (unbound if special populations), initiate maintenance dosing